Claims
- 1. A pharmaceutical composition consisting essentially of a pharmaceutically suitable carrier and an effective amount of a compound of the formula ##STR1537## or a pharmaceutically acceptable salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional carbocyclic aromatic ring fused to the first ring, the total number of carbocyclic fused rings being 3-5, the sole heterocyclic substituents on said fused rings being Het.sup.1 and Het.sup.2.
- one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from
- (a) 2, 3, or 4-pyridyl,
- (b) 2, 4, or 5-pyrimidinyl,
- (c) 2-pyrazinyl,
- (d) 3, or 4-pyridazinyl,
- (e) 3, or 4-pyrazolyl,
- (f) 2, or 3-tetrahydrofuranyl, and
- (g) 3-thienyl.
- 2. The composition of claim 1 wherein the first ring of said compound is a 5- or 6-membered ring and at least one fused additional ring is a 6-membered aromatic ring.
- 3. The composition of claim 1 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 4. The composition of claim 1 wherein one of Het.sup.1 and Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 5. The composition of claim 2 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 6. The composition of claim 2 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 7. The composition of claim 1 wherein Het.sup.1 and Het.sup.2 are selected from:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 8. The composition of claim 2 wherein Het.sup.1 and Het.sup.2 are selected from:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 9. A compound having the formula ##STR1538## or a pharmaceutically acceptable salt thereof wherein each J, K, L and M independently are CR.sup.1, CR.sup.5 or CR.sup.2 ;
- A is ##STR1539## n is 0, 1, 2 or 3; R.sup.1 and R.sup.2 independently are H, halo, alkyl of 2-3 carbon atoms, acetyl OR.sup.3, NO.sub.2, CN, NR.sup.3 R.sup.4, or fluoroalkyl of 1-3 carbon atoms;
- R.sup.3 and R.sup.4 independently are H, alkyl of 1-3 carbon atoms, or acyl, B and D independently are R.sup.1 or R.sup.2, or, when A is (CH.sub.2).sub.o can be taken together to form --CH.dbd.CH--, or --CH.sub.2 --CH.sub.2 --;
- R.sup.5 independently is H, or is taken together with R.sup.1 to form a 2,3- or a 3,4-fused benzo ring;
- one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4 or 5-pyrimidinyl and the other is selected from:
- (a) 2, 3, or 4-pyridyl,
- (b) 2, 4, or 5-pyrimidinyl,
- (c) 2-pyrazinyl,
- (d) 3, or 4-pyridazinyl,
- (e) 3, or 4-pyrazolyl,
- (f) 2, or 3-tetrahydrofuranyl, and
- (g) 3-thienyl.
- 10. A compound of claim 9 wherein B and D in the formula are both H and the formula is: ##STR1540## wherein A, R.sup.1, R.sup.2, R.sup.5, Het.sup.1 and Het.sup.2 are as defined in claim 9.
- 11. A compound of claim 10 wherein A is (CH.sub.2).sub.n, ##STR1541## CHOH, or C.dbd.NOH.
- 12. A compound of claim 10 wherein R.sup.1 and R.sup.5 are H and R.sup.2 is H, halo, alkyl of 1-3 carbon atoms, OR.sup.3, NH.sub.2, or fluoroalkyl of 1-3 carbon atoms.
- 13. A compound of claim 10 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 14. The compound of claim 10 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 15. A compound of claim 10 wherein Het.sup.1 and Het.sup.2 are selected from:
- (a) 4-pyridyl and 4-pyridyl.
- (b) 4-pyrimidinyl and 4-pyrimidinyl.
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 16. A compound of claim 10 wherein A is (CH.sub.2).sub.o, ##STR1542## CHOH, or C.dbd.NOH; R.sup.1 and R.sup.5 are H; R.sup.2 is H, halo, alkyl of 1-3 carbon atoms, OR.sup.3, NH.sub.2, or fluoroalkyl of 1-3 carbon atoms; one of Het.sup.1 or Het.sup.2 is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 17. A compound of claim 16 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 18. A compound of claim 10 which is 9,9-bis(4-pyridinylmethyl)anthrone dihydrochloride.
- 19. The compound of claim 10 which is 9,9-bis(4-pyridinylmethyl)fluorene dihydrochloride.
- 20. The compound of claim 10 which is 9,9-bis(4-pyridinylmethyl)-2-acetylfluorene dihydrochloride.
- 21. A compound of claim 9 wherein B and D in the formula are taken together to form --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 -- and the formula is ##STR1543## wherein R.sup.1, R.sup.2, R.sup.5, Het.sup.1 and Het.sup.2 are as defined in claim 9.
- 22. A compound of claim 21 wherein R.sup.1 and R.sup.5 are H and R.sup.2 is H, halo, alkyl of 1-3 carbon atoms, OR.sup.3, NH.sub.2, or fluoroalkyl of 1-3 carbon atoms.
- 23. A compound of claim 21 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 24. The composition of claim 21 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 25. A compound of claim 21 wherein Het.sup.1 and Het.sup.2 are selected from:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 26. A compound of claim 22 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 27. A compound of claim 22 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 28. A compound of claim 22 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (c) 4-pyridyl and 3-tetrahydrofuranyl.
- 29. The compound of claim 21 which is 9,9-bis(4-pyridinylmethyl)cyclopenta[def]phenanthrene.
- 30. The compound of claim 21 which is 9,9-bis(4-pyridinylmethyl)-4,5-dihydrocyclopenta[def]phenanthrene.
- 31. A compound of claim 9 wherein A is (CH.sub.2).sub.o ; B and D are R.sup.1 and R.sup.2 ; J, K.sub.2, L.sub.3 and M.sub.4 are CR.sup.1 or CR.sup.5 ; J.sub.8, K.sub.7, L.sub.6 and M.sub.5 are CR.sup.2.
- 32. A compound of claim 31 wherein R.sup.1 and R.sup.5 are H and R.sup.2 is H, halo, alkyl of 1-3 carbonatoms, OR.sup.3, NH.sub.2, or fluoroalkyl of 1-3 carbon atoms.
- 33. A compound of claim 32 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2,4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 34. A compound of claim 32 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 35. A compound of claim 32 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tertrahydrofuranyl.
- 36. A compound having the formula: ##STR1544## or a pharmaceutically acceptable salt thereof wherein a is a single bond or double bond;
- X and Y taken together when a is a single bond is ##STR1545## X and Y taken together when a is a double bond is ##STR1546## where n is 1 or 2; Q when a is a single bond is .dbd.O, .dbd.S, H.sub.2, [OR.sup.3,].dbd.NOR.sup.1, ##STR1547## --(H)F, .dbd.NOR.sup.1, F.sub.2, (R.sup.1)OR.sup.3, .dbd.CR.sup.1 R.sup.2 ;
- Q when a is a double bond is R.sup.2, OR.sup.3 or halo;
- p is 2 or 3;
- R.sup.1 is H, alkyl of 1-10 carbon atoms, cycloalkyl of 3-8 carbon atoms, or ##STR1548## R.sup.2 is R.sup.1, NO.sub.2, CN, CO.sub.2 R.sup.1, ##STR1549## or halo; R.sup.3 is R.sup.1 or ##STR1550## W, Z independently are H, halo, alkyl of 1-3 carbon atoms, OR.sup.3, NO.sub.2, CF.sub.3, fluoroalkyl, CN, or N(R.sup.1).sub.2 ; and
- one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from
- (a) 2, 3, or 4-pyridyl,
- (b) 2, 4, r 5-pyrimidinyl,
- (c) 1-pyrazinyl,
- (d) 3, or 4-pyridazinyl,
- (e) 3, or 4-pyrazolyl,
- (f) 2, or 3-tetrahydrofuranyl, and
- (g) 3-thienyl.
- 37. A compound of claim 36 wherein X and Y in the formula are taken together, a is a single bond, and the formula is: ##STR1551## wherein Q, W, Z, Het.sup.1 and Het.sup.2 are as defined in claim 36.
- 38. A compound of claim 37 wherein Q is .dbd.O, .dbd.S, H.sub.2, .dbd.CR.sup.1 R.sup.2, or (R.sup.1)OR.sup.3.
- 39. A compound of claim 38 wherein W and Z each is H or OCH.sub.3.
- 40. A compound of claim 38 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 41. A compound of claim 37 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 42. A compound of claim 37 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 43. A compound of claim 37 wherein Q is .dbd.O, .dbd.S, H.sub.2, .dbd.CR.sup.1 R.sup.2, or (R.sup.1)OR.sup.3 ; W and Z each is H or OCH.sub.3 ; one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 44. A compound of claim 43 wherein R.sup.1 is H, CH.sub.3 or phenyl; R.sup.2 is H; and R.sup.3 is H or ##STR1552##
- 45. A compound of claim 44 wherein one of Het.sup.1 l or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 46. A compound of claim 44 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 47. The compound of claim 37 which is 2,2-bis(4-pyridinylmethyl)-1(2H)acenaphthylenone dihydrochloride.
- 48. The compound of claim 37 which is 4((1,2-dihydro-2-methylene-1-(4-pyridinylmethyl)-1-acenaphthylene-1-ylmethyl)) pyridine dihydrochloride.
- 49. A compound having the formula: ##STR1553## or a pharmaceutically acceptable salt thereof wherein a is a single bond or double bond;
- b is a single bond or double bond, provided one of a or b is a single bond;
- X independently when a and b are single bonds and not connected to V is CR.sup.1 R.sup.2, CQ, C(R.sup.1)OR.sup.3, or --(--CH.sub.2 --)--.sub.n where n is 1, 2 or 3;
- X independently when one of a or b is a double bond and not connected to V is CR.sup.2, or COR.sup.3 ;
- A is a single bond, --(--CR.sub.2.sup.1).sub.n --, --X--, --(--CR.sub.2.sup.1 ).sub.n --X, where n is 1, 2 or 3 and X is as defined above when a is a single bond;
- Y and V taken together when A and b are single bond is ##STR1554## Y and V taken together when A is a single bond is --CH.sub.2 --(--CH.sub.2 --).sub.m --CH.sub.2 --where m is 1 or 2;
- provided that when Y and V are connected, then V and X are not connected;
- V and X taken together when b is a double bond is C--CH.dbd.CH--CH.dbd.CH--C--, or, C--(--CH.sub.2 --).sub.p --C;
- provided that when V and X are connected, then Y and V are not connected;
- Q when a is a single bond is .dbd.O, --S, H.sub.2, [OR.sup.3,].dbd.NOR.sup.1, ##STR1555## --(H)F, F.sup.2, (R.sup.1)OR.sup.3, .dbd.CR.sup.1 R.sup.2 ; Q when a is a double bond is R.sup.2, OR.sup.3 or halo;
- p is 2 or 3;
- R.sup.1 is H, alkyl of 1-10 carbon atoms, cycloalkyl of 3-8 carbon atoms, or ##STR1556## R.sup.2 is R.sup.1, NO.sub.2, CN, CN.sub.2 R.sup.1, ##STR1557## or halo; R.sup.3 is R.sup.1 or ##STR1558## W, Y, Z independently are H, halo, alkyl of 1-3 carbon atoms, OR.sup.3, NO.sub.2, CF.sub.3, fluoroalkyl, CN or N(R.sup.1).sub.2 ; and
- one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from
- (a) 2, 3, or 4-pyridyl,
- (b) 2, 4, or 5-pyrimidinyl,
- (c) 2-pyrazinyl,
- (d) 3, or 4-pyridazinyl,
- (e) 3, or 4-pyrazolyl,
- (f) 2, or 3-tetrahydrofuranyl, and
- (g) 3-thienyl.
- 50. A compound of claim 49 wherein Y and V are taken together, b is a single bond, A is a single bond and the formula is: ##STR1559## wherein a, Q, X, W, Z, Het.sup.1 are Het.sup.2 are as defined in claim 49.
- 51. A compound of claim 50 wherein a is a single bond.
- 52. A compound of claim 51 wherein Q is .dbd.O, .dbd.S, .dbd.CR.sup.1 R.sup.2, or (R.sup.1)OR.sup.2.
- 53. A compound of claim 51 wherein X is CR.sup.1 R.sup.2.
- 54. A compound of claim 51 wherein W and Z each is H or OCH.sub.3.
- 55. A compound of claim 51 wherein one of Het.sup.1 or Het.sup.2 is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 56. A compound of claim 51 wherein one of Het.sup.1 or Het.sup.2 is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 57. A compound of claim 51 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 58. A compound of claim 51 wherein Q is .dbd.O, .dbd.S, .dbd.CR.sup.1 R.sup.2, or (R.sup.1)OR.sup.3 ; X is .dbd.CR.sup.1 R.sup.2 ; W and Z each is H or or OCH.sub.3 ; one of Het.sup.1 or Het.sup.2 is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4 or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 59. A compound of claim 58 wherein R.sup.1 is H, CH.sub.3 or phenyl; R.sup.2 is H; and R.sup.3 is H, ##STR1560## or phenyl,
- 60. A compound of claim 59 wherein one of Het.sup.1 or Het.sup.2 is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 61. A compound of claim 59 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 62. A compound of claim 49 wherein V and X are taken together, b is a double bond, and a is a single bond, and the formula is: ##STR1561## wherein Q, W, Z, Y, Het.sup.1 and Het.sup.2 are as defined in claim 80, and A is (CH.sub.2).sub.n, where n is 0, 1 and 2.
- 63. A compound of claim 62 wherein Q is .dbd.O, .dbd.S, .dbd.CR.sup.1 R.sup.2, or (R.sup.1)OR.sup.3.
- 64. A compound of claim 62 wherein W, Y and Z each is H or OCH.sub.3.
- 65. A compound of claim 62 wherein one of Het.sup.1 or Het.sup.2 is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 66. A compound of claim 62 wherein one of Het.sup.1 or Het.sup.2 is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 67. A compound of claim 62 wherein Het.sup.1 and Het.sup.2 are:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 68. A compound of claim 62 wherein Q is .dbd.O, .dbd.S, .dbd.CR.sup.1 R.sup.2, or (R.sup.1)OR.sup.3, W, Y, and Z each is H or OCH.sub.3 ; one of Het.sup.1 or Het.sup.2 is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 69. A compound of claim 68 wherein R.sup.1 is H, CH.sub.3 or phenyl; R.sup.2 is H; and R.sup.3 is H or ##STR1562##
- 70. A compound of claim 69 wherein one of Het.sup.1 or Het.sup.2 is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 71. A compound of claim 69 wherein one of Het.sup.1 or Het.sup.2 is
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 72. The compound of claim 62 which is 11,11-bis(4-pyridinylmethyl)-5H-dibenzo[a,d]cyclohepten-10(11H)-one, dihydrochloride.
- 73. A pharmaceutical composition consisting essentially of a pharmaceutically suitable carrier and an effective amount of a compound of any of claims 9, 19, 20-25, 37-49, 50-61, or 62-72.
- 74. A method of treating a neurological disorder in a mammal comprising administering to the mammal an effective amount of a compound of the formula ##STR1563## or a pharmaceutically acceptable salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional carbocyclic aromatic ring fused to the first ring, the total number of carbocyclic fused rings being 3-5, the sole heterocyclic substituents on said fused rings being Het.sup.1 and Het.sup.2,
- one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from
- (a) 2, 3, or 4-pyridyl,
- (b) 2, 4, or 5-pyrimidinyl,
- (c) 2-pyrazinyl,
- (d) 3, or 4-pyridazinyl,
- (e) 3, or 4-pyrazolyl,
- (f) 2, or 3-tetrahydrofuranyl, and
- (g) 3-thienyl.
- 75. The method of claim 74 wherein the first ring of said compound is a 5- or 6-membered ring and at least one fused additional ring is a 6-membered aromatic ring.
- 76. The method of claim 74 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 77. The method of claim 74 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 78. The method of claim 75 wherein one of Het.sup.1 or Het.sup.2 of said compound is 2, 3 or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is 2, 3, or 4-pyridyl, 2, 4, or 5-pyrimidinyl or 2, or 3-tetrahydrofuranyl.
- 79. The method of claim 75 wherein one of Het.sup.1 or Het.sup.2 of said compound is 4-pyridyl or 4-pyrimidinyl and the other is 4-pyridyl, 4-pyrimidinyl, or 3-tetrahydrofuranyl.
- 80. The method of claim 74 wherein Het.sup.1 and Het.sup.2 are selected from:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 81. The method of claim 75 wherein Het.sup.1 and Het.sup.2 are selected from:
- (a) 4-pyridyl and 4-pyridyl,
- (b) 4-pyrimidinyl and 4-pyrimidinyl,
- (c) 4-pyridyl and 4-pyrimidinyl, or
- (d) 4-pyridyl and 3-tetrahydrofuranyl.
- 82. A method of treating a neurological disorder in a mammal comprising administering to the mammal an effective amount of a compound of any of claims 9-19, 20-35, 37-49, 50-61, or 62-72.
- 83. A compound of the formula ##STR1564## or a pharmaceutically acceptable salt thereof wherein X and Y are taken together to form a saturated or unsaturated carbocyclic first ring and the shown carbon in said ring is .alpha. to at least one additional carbocyclic aromatic ring fused to the first ring, the total number of carbocyclic fused rings being 3-5, the sole heterocyclic substituents on said fused rings being Het.sup.1 and Het.sup.2,
- one of Het.sup.1 or Het.sup.2 is 2, 3, or 4-pyridyl or 2, 4, or 5-pyrimidinyl and the other is selected from
- (a) 2, 3, or 4-pyridyl,
- (b) 2, 4, or 5-pyrimidinyl,
- (c) 2-pyrazinyl,
- (d) 3, or 4-pyridazinyl,
- (e) 3, or 4-pyrazolyl,
- (f) 2, or 3-tetrahydrofuranyl, and
- (g) 3-thienyl.
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of co-pending application Ser. No. 07/105,156, filed Oct. 6, 1987, now abandoned, which is a continuation-in-part of application Ser. No. 944,953, filed Jan. 5, 1987, now U.S. Pat. No. 4,760,083 which in turn is a continuation-in-part of application Ser. No. 06/850,015, filed Apr. 10, 1986, now abandoned.
US Referenced Citations (16)
Foreign Referenced Citations (21)
Number |
Date |
Country |
742389 |
Nov 1968 |
BEX |
777752 |
Jan 1971 |
BEX |
808347 |
Dec 1972 |
BEX |
897993 |
Oct 1982 |
BEX |
0005143 |
Nov 1979 |
EPX |
147805 |
Dec 1983 |
EPX |
2704934 |
Feb 1976 |
DEX |
3405332 |
Feb 1984 |
DEX |
49-085073 |
Dec 1972 |
JPX |
54-125662 |
Mar 1978 |
JPX |
56-073073 |
Nov 1979 |
JPX |
56-077263 |
Nov 1979 |
JPX |
55-129284 |
Oct 1980 |
JPX |
60-139630 |
Dec 1983 |
JPX |
59-98896 |
Jun 1984 |
JPX |
61-282348 |
Jun 1985 |
JPX |
443344 |
Dec 1964 |
CHX |
656378 |
May 1983 |
CHX |
897052 |
Mar 1959 |
GBX |
936782 |
Mar 1959 |
GBX |
936783 |
Mar 1959 |
GBX |
Non-Patent Literature Citations (3)
Entry |
Research Disclosures, 184; pp. 446-454 (1979). |
J. Heterocyclic Chem., 19; pp. 1013-1016 (1982). |
Eur. J. Med. Chem.--Chem. Ther. 16(4); pp. 373-378 (1981). |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
105156 |
Oct 1987 |
|
Parent |
944953 |
Jan 1987 |
|
Parent |
850015 |
Apr 1986 |
|